◆ 会议时间：2025年6月21-25日
◆ 会议地点：美国 华盛顿

◆ 会议简介：

2025年第33届国际血栓与止血学会(ISTH)大会/年会将于2025年6月21-25日在美国华盛顿举行。ISTH大会是血栓与止血领域最具影响力的国际盛会，数千名世界一流的血栓、止血和血管生物学专家将齐聚一堂，一起展示最新的研究成果，交流最新的科学发现，并论旨在改善患者护理的最新临床应用，促进对血栓和出血性疾病的全面认识、预防、诊断和治疗。ISTH大会原每两年举办一次，从2020年开始改为每年举办一次ISTH年会。

国际血栓与止血学会(ISTH)是一个全球性的非营利性会员组织，成立于1954年，起初命名为国际血栓与止血委员会，1969年正式更为现名。ISTH的使命是宣促进对血栓和出血性疾病的认识、预防、诊断和治疗，包括血小板功能及其调节，血栓形成、纤溶和溶栓机制，以及血栓栓塞性疾病等新兴领域。ISTH发展至今，已成为全球领先的血栓与止血相关的专业组织，在全球98个国家和地区拥有超过5000名成员。未经许可禁止复制摘录转载本站任何内容-国际医学会议网（lingyuint.com）。

The XXXIII Congress of the International Society on Thrombosis and Haemostasis (ISTH 2025)

Date:
June 21-25, 2025

Venue:
Washington, D.C., USA

以下为上届会议信息

摘要征文投稿：

Important Dates

• December 1, 2023: Abstract submission opens

• January 17, 2024 at 17:00 EST (U.S.): Abstract Submission Website Closes

• Early April 2024: Abstract Notifications Sent to Presenting Authors Only

• May 8, 2024: Late-Breakthrough Abstract Submission Website Launches

• May 10, 2024: Abstract Withdrawal Deadline and Presenting Author Registration Deadline

• May 10, 2024: Deadline for accepting changes to the author list. No exceptions will be made.  Presenting author changes (from the existing author list) will be considered on a case-by-case basis and all requests must be sent by email to abstracts@isth.org.

• May 15, 2024 at 17:00 EST (U.S.): Late-Breakthrough Abstract Submission Website Closes

• May 17, 2024: Abstract Titles Released (only confirmed participating abstract titles will be released)

• June 7, 2024 at 09:00 EST (U.S.): Full text of abstracts released (excludes Late-Breakthrough abstracts)

点此提交摘要>>>Submit Abstract>>>

Preparing an Abstract for Submission
Authors and Co-Authors

• The first/presenting author is responsible for ensuring that all authors have read the abstract and agreed to be co-authors.

• The presenting author of the abstract must be registered for the congress. Abstract(s) will be withdrawn if registration is not completed by the presenting author by May 10, 2024.

• The submission of an abstract constitutes a formal commitment by the submitting (presenting) author to present the abstract in-person (if accepted) in the session and the time assigned by the Scientific Committee. Registration fees will not be waived and no virtual presentations will be allowed.

• A maximum of 20 authors is permitted on each abstract, plus one (1) group.

• Adding Co-authors: please fill out the family names, first names, and institution, city, country and email addresses of each co-authors.

• Based on current accreditation guidelines, if the presenting author is employed by industry, an alternate presenter who does not have a relevant employment relationship must be named if the abstract is selected for presentation in an Oral Communication session.

Conflict of Interest

• It is the intent of the ISTH to provide high-quality sessions focused on educational content that is free from commercial influence or bias. Thus, the submitting/presenting author of an abstract is required to declare any potential conflicts of interest for the presenting author during abstract submission.

• The submitting/presenting author should be prepared to have each co-author complete and sign a conflict of interest disclosure.

Abstract Body

• For standardization, the acceptable length of the abstract is a maximum of 300 words. This does not include the author’s details, titles, tables and figures.

• Title: Clearly indicate the nature of the investigation. The abstract title and text may not contain trade names. The Scientific Committee reserves the right to replace trade names in accepted abstracts.

• Background

• Aims

• Methods: Which should contain sufficient information to be able to understand the experimental design, the analytical techniques and the statistics used in the study

• Results: Which should contain objective data to answer the scientific question(s). A maximum of two total tables or figures may be submitted with this section. Please be sure to number each table and figure and cite each table and figure in the abstract text.

• Conclusion (or Conclusions): Which should provide only conclusions of the study directly supported by the results, along with implications for clinical practice, avoiding speculation and overgeneralization.

• Other Items for Consideration

  • In clinical studies, please state whether informed consent was obtained and whether the study was approved by a recognized medical ethics committee.

  • If the research included in your abstract was supported by a pharmaceutical or diagnostics company, you can indicate this when submitting your abstract.

  • Please indicate the funding agency of your work if applicable. There is not a specific area to enter this information, it will need to be included as part of the abstract text.

  • Abbreviations should be defined.

  • If off-label use of drugs was involved in the study, please state this clearly.

Figures and Table

• Figures and tables may be submitted with a maximum file size is 2 MB w. Figures are allowed in the following formats: PNG, GIF, JPG.

• Your abstract may contain two (2) figures or tables; this can be a combination of the following: two (2) figures, two (2) tables, or one (1) figure and one (1) table.

• You will be asked to include a heading for each of your figures/tables to be included as part of the formal published abstract supplement. The heading(s) for figures/tables is not included in the 300 words allotted for the abstract.

• Acquired and Critical Care Bleeding
• Arterial Thromboembolism
• Coagulation Factors and Co-Factors
• Diagnostics, OMICs and Advanced Technologies
• Fibrinogen, Factor XIII, and Fibrinolysis
• Inherited Bleeding Disorders and Inhibitors
• Modulators of Coagulation and von Willebrand Factor
• Nurses and Allied Health
• Pediatric Hemostasis and Thrombosis
• Platelet Disorders
• Platelets and Megakaryocytes
• Vascular Biology, Blood Cells, and Immunothrombosis
• Venous Thromboembolism
• Women's Hemostasis and Thrombosis​​

• Perioperative Bleeding
• Coagulopathy of Trauma
• Massive Transfusion Management
• Coagulopathy of Liver and Renal Disease
• Coagulopathy of Other Systemic Diseases
• Antithrombotic Associated Bleeding

• Coronary Artery and Cardiac Disease
• Atrial Fibrillation
• Cerebrovascular Disease
• Peripheral Vascular Disease
• Diagnosis of ATE
• ATE Treatment and Prevention

• Synthesis and Biochemistry
• Protein Structure and Function
• Non-hemostatic Roles of Coagulation Proteins

• Diagnostic Laboratory Methods
  • ​Abstracts that describe, evaluate, or validate a clinical coagulation or platelet laboratory assay.
• Genomics and Transcriptomics
  • Abstracts in which genomics or transcriptomic approaches are used.
• Proteomics, Metabolomics, and Lipidomics
  • ​Abstracts in which novel proteomic, metabolomics, or lipidomic approaches are used.
• Novel Research Methods
  • ​Abstracts that describe, evaluate, or validate novel research methods Abstracts describing, evaluating, or validating novel diagnostic laboratory methods for the clinical coagulation laboratory should be submitted to the “Diagnostic Laboratory Methods” subcategory.
• Artificial Intelligence/Machine Learning
  • Abstracts that use AI or machine learning approaches.​
• Mathematical and Computational Models
  • ​Abstracts that use mathematical or computational modeling approaches.
• Novel Experimental Models in Hemostasis and Thrombosis Disease
  • ​Abstracts that describe, evaluate, or validate novel experimental in vitro or in vivo models applicable to all areas of hemostasis and thrombosis including platelet and vascular biology.

• Fibrinogen Structure and Function
• Factor XIII and Other Transglutaminases
• Fibrinolysis and Proteolysis
• Regulation of Fibrinolysis

• Hemophilia
• Von Willebrand Disease
• Rare Factor Deficiencies
• Acquired Factor Deficiencies/Inhibitors
• Vascular Disorders

• Protein C/S Pathway
• Antithrombin and Other Serpins
• TFPI
• Non-hemostatic Roles of Anticoagulant Proteins
• von Willebrand Factor
• ADAMTS13 and Other Proteases

• Nurses and Allied Health

• Neonatal Coagulation Disorders
• Perioperative and Critical Care Coagulation
• Pediatric Bleeding and Thrombosis
• Bleeding and Thrombotic Issues in Adolescence

• Inherited Platelet Disorders
• Immune Thrombocytopenia - ITP, HIT, VITT
• Thrombotic Microangiopathy
• Myeloproliferative Neoplasms and Clonal Disorders
• Acquired Platelet Disorders

• Megakaryocyte Biology
• Platelet Biology
• Non-hemostatic Roles of Platelets
• Receptors and Signaling

• Blood Vessel Structure and Function
• Endothelial Cell Biology
• Inflammation and Thrombosis
• Infection and Immunity
• Extracellular vesicles
• Red Cell Disorders and Coagulation

• Deep and Superficial Vein Thrombosis
• Pulmonary Embolism
• Long-term Complications of VTE
• Unusual Site VTE
• Diagnosis of VTE
• VTE Treatment and Prevention
• Thrombophilia
• Cancer-associated Thrombosis

• Menstrual Bleeding Disorders
• Hormonal Modulation of Coagulation
• Pregnancy
• Bleeding and Thrombotic Issues in Aging/Postmenopausal Women

ISTH2024 注册费：

• In-Person Registration includes:​
  • Access to Education and Scientific Sessions
  • Access to Exhibit Hall
  • Access to Opening Plenary/ISTH Awards Ceremony and Welcome Reception
  • Access to Poster Sessions 
  • Access to Supported Symposia and Presentation Theaters
  • Lunch
  • Coffee Breaks on each day of the Congress
• In-Person Registration does not include:
  • Access to the On-Demand platform (this is an additional charge)
  • Access to CME Credits (requires an additional $25.00 USD charge)
  • Access to the ISTH 2024 Networking Evening* (requires an additional $65.00 USD charge)
    The ISTH 2024 Networking Evening will take place separately from the ISTH 2024 Congress.
• On-Demand Registration includes:
  • Access to all sessions on-demand, within 24 hours after the live session, available for 30 days after the Congress.
  • Note: CME accreditation is not available for on-demand content

• Early Registration Deadline: April 19, 2024 
• On-Site Registrations Begin: June 19, 2024
• Cancellation Deadline: May 22, 2024

◆ 参会对象：医生、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。